We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New International Clinical Trial Register

By Biotechdaily staff writers
Posted on 28 May 2003
A new online service provides unique numbers to randomized controlled trials in all areas of healthcare and from all countries in the world. More...
This service, designed to address the current confusion experienced by the clinical trials community, is called the International Standard Randomized Controlled Trial Number (ISRCTN) Register.

Currently, several trials may have the same title, one may be reported in several places under different titles, and many trials are never reported. The new register assigns a unique number to each randomized controlled trial in order to track the trial unambiguously throughout its life cycle. The register is being launched after a successful pilot by the UK Medical Research Council and the UK Coordinating Committee for Cancer Research. To date, more than 80 organizations that have sponsored trials have already registered, and the database now contains more than 750 records.

Several trial registers are in existence with their own numbering schemes. Also, specific registers exist for diseases such as Alzheimer's and diabetes. The US National Library of Medicine has created a website providing details of trials in the United States. The new register is unique, however, since it is not limited to a specific disease or geographic area. Medical journals are being encouraged to allow authors to include their ISRCTN in any research they publish, so that the trials can be easily identified in databases such as MEDLINE and PubMed.

"Acting rather like the ISBN (International Standard Book Number) on the back of every book, the ISRCTN will simplify the identification of trials and provide a unique number that can be used to track all publications and reports resulting from each trial,” said Anne Greenwood, managing director, Current Controlled Trials Ltd. (London, UK), which developed the register. Registering details are provided on the company's website (www.controlled-trials.com).





Related Links:
Current Controlled Trials

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.